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Abstract 
ABSTRACT'
AKT/PKB is an oncogenic serine/threonine kinase regulated via the PI3K pathways. 
14-3-3s represent a large group of adaptor proteins that are known to interact with a 
plethora of signaling proteins and regulate diverse signal transduction pathways. 
The B-cell antigen receptor (BCR) activation and signalosome assembly are 
dynamic processes controlled by protein phosphorylation. The signaling events 
share their functions in controlling cell proliferation, differentiation, and/or 
apoptosis. 
In Paper I, the first characterized protein is 14-3-3ζ, which was found to be a new 
regulator of BTK. Two 14-3-3ζ binding-sites were found to be phosphorylated by 
AKT/PKB and mapped to phospho-serine pSer51 in the PH domain and to 
phospho-threonine pThr495 in the kinase-domain. The PI3K inhibitor LY294002 
abolished S51/T495 phosphorylation and disrupted the interaction. Moreover, 
inhibitors targeting 14-3-3 (BV02) and BTK (Ibrutinib) compromised interaction 
between the two proteins. Nuclear translocation of BTK was promoted following 
down regulation of 14-3-3ζ. Furthermore, the loss-of-function mutant S51A/T495A 
displayed reduced tyrosine-phosphorylation and inability to bind to 14-3-3ζ. 
Conversely, the gain-of-function mutant S51D/T495D exhibited intense 
phosphorylation, enhancing interaction of BTK with 14-3-3 ζ. Phosphorylation of 
this mutant was associated with ubiquitination and degradation of the protein, 
presumably, contributing to the termination of the B-cell receptor signaling. 
In Paper II, we identified a new BTK-partner, ankyrin repeat domain 54 protein 
(ANKRD54) that binds to the BTK SH3 domain. Our results suggest that 
ANKRD54 specifically mediates nuclear export of both BTK and another TEC 
family kinase member, TXK/RLK. The interaction site was mapped to the C-
terminus of the BTK SH3 domain, since a synthetic peptide covering this region, 
ARDKNGQEGYIPSNYVTEAEDS, was sufficient for mediating this interaction. 
ANKRD54 is the first protein reported to specifically influence nucleo-cytoplasmic 
shuttling of BTK. ANKRD54 probably belongs to a novel group of proteins 
carrying out this activity in a Crm1-dependent manner. 
In Paper III, using proteomics, we identified 446 proteins, containing 186 novel 
AKT-associated-motif (RXRXXS/T) phosphorylation events. B-cell receptor 
induction leads to up regulation of 85 proteins and down regulation of 277 proteins. 
Proteins related to ribosome biogenesis, DNA binding, transcription and translation 
regulation were mainly up regulated. Conversely, down regulated proteins were 
mainly involved in RNA binding, mRNA splicing and mRNP export. 
Immunoblotting of two proteins RBM25 and MEF-2D were positively validated in 
the mass spectrometry data. Consistent with these findings, the AKT-inhibitor 
(MK-2206) remarkably reduced phosphorylation of the target proteins on the 
RXRXXpS/T motif, while the mTORC2-inhibitor (PP242) totally blocked this 
phosphorylation.  
In Paper IV, we found that AKT/PKB induces BLNK and SYK phosphorylation, 
which promotes the 14-3-3 binding in a Ser/Thr phosphorylation-dependent 
manner. Using an in vitro phosphorylation screening assay, we identiﬁed BLNK 
and SYK as excellent substrates of AKT. Moreover, the AKT/PKB inhibitor 
MK2206 reduced phosphorylation of BLNK and SYK. Additionally, 14-3-3 
regulates the stable interaction between SYK and BLNK and sustains 
phosphorylation of SYK and BLNK. Furthermore, 14-3-3 compromises binding of 
SYK to Importin 7 thereby abrogating shuttling of the protein to the nucleus. Alanine 
substitutions of T256, S295 or S297 sites resulted in abrogation of SYK binding to 
Importin 7. Interestingly, BLNK phosphorylation at Y84 appears to correlate with the 
degree of tyrosine phosphorylation of SYK at position(s) Y525/526. 
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Chapter I: Introduction 
1 INTRODUCTION 
1.1 HEMATOPOIESIS 
Hematopoiesis is the process of generation of all blood cell lineages 
originated from hematopoietic stem cells (HSCs), which resides in the Bone 
Marrow (BM) [1]. HSCs are capable of self-renewing and have the ability to 
give rise to the different blood cell types [2]. Various signaling molecules and 
transcription factors have been recognized to modulate the response of the 
downstream target genes required for hematopoietic lineage development [3]. 
The first progenitors to be generated from HSCs are the so-called multi-lineage 
progenitors (MLPs) that can differentiate into common lymphoid progenitor 
(CLP) or common myeloid progenitors (CMP) to produce all blood cells. The 
latter are Erythropoiesis (the formation of red blood cells), Leucopoiesis (the 
formation of white blood cells) and Thrombopoiesis (the formation of platelets) 
[2, 4]. Blood cells normally consist of red blood cells, platelets and white blood 
cells, which include granulocytes (neutrophils, eosinophils and basophils), and 
non-granulocytes (monocytes as well as T and B lymphocytes). Several human 
diseases affecting the hematopoietic system, such as leukemias and 
hemoglobinopathies are a serious public health problem [5].  
The function of blood cells varies according to the cell types. For example, 
red blood cells transport oxygen to all tissues, while platelets take part in blood 
coagulation during wound healing. A major function of white blood cells is to 
provide protection against pathogens. The main white blood cells making up the 
immune system include Natural killer cells (NK cells), Dendritic cells (DCs), 
Neutrophils, Eosinophils, Basophiles, Macrophages, T cells and B cells and their 
secreted effectors [6, 7]. 
1.2 B LYMPHOCYTES (B CELLS) 
B lymphocytes or B cells start maturation in the BM. During B cell 
development, in the Pro-B cell type, where the first gene rearrangement takes 
place. The Pro-B cells then developed to Pre-B cells, which express the µ chain 
on their surface. At this stage, B cells start to express surrogate light chains (λ5 
and VpreB) genes [8]. Next, B cells start to express functional Ig molecules on 
their surface and are transformed into immature B cells, which circulate in the 
periphery to become mature B cells. Thereafter, they distribute in the periphery 
for a short period and die unless they encounter antigen. B cell activation and 
IgD down regulation occurs following antigen binding in the lymphoid organs 
[9]. B cells are important members of the adaptive immunity and are responsible 
for the production of plasma cells and secretion of antibodies (immunoglobulins) 
against pathogenic microbes. In addition, B lymphocytes are involved in diverse 
immunological functions and are, in principle, considered as positive regulators 
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of the immune response. Generally, the role of B cells is to recognize 
extracellular pathogens that are internalized and subsequently processed to 
peptides for antigen presentation through MHC-II (major histocompatibility 
complex class II) molecules. By carrying out this elaborate task, B lymphocytes 
are able to provide supportive signals to specific CD4+ THelper cells (TH) [10]. 
Association of B cells and TH cells facilitates the secretion of antibodies against 
pathogens, which are eliminated and therefore it is called T cell dependent (TD) 
B cell response. B cells can also stimulate immune response against pathogens 
without the help of T-cells, which is termed T cell independent (TI) response 
[11-13]. In addition to antibody (Ab) generation and antigen (Ag) presentation, 
B cells can also secrete different cytokines that influence the immune response 
[14, 15]. 
The IgM+CD10+ transitional cells are a subset of B lymphocytes that leave 
the BM and undergo several developmental phases as they migrate into the 
peripheral lymphoid tissues [16]. B cell expansion in the periphery is primarily 
dependent on the Ag-recognition process occurring in the secondary lymphoid 
organs, which serve as a microenvironment suitable for this event. In contrast, B 
cells that fail in Ag-recognition undergo apoptosis. Furthermore, B cells can 
proliferate and differentiate into memory cells as well as antibody (Ab)-secreting 
plasma cells (PCs) upon Ag encounter, cytokine signals and T cell interaction 
[17-19]. Additionally, B cell expansion, somatic hypermutation (SHM) and 
isotype-switching occur in the germinal center (GC) [20]. In the absence of 
antigenic stimulation, memory B cells can survive for a long period of time [21]. 
They can also enter the lymphoid organs upon antigenic stimulation and 
circulate in the periphery to participate in the secondary antibody response 
triggered by contact with TH cells [22]. Two distinct groups of B lymphocytes 
exist; B1 and B2 cells. B1 cells generate normal Abs and mainly localize in the 
peritoneal cavity and gut-associated lymphoid tissues. B1 cells normaly 
originate from the fetal-liver and have the capacity of self-renewing. B1 cells are 
also subdivided into two subsets based on the CD5 expression: B-1a cells 
(CD5+) and B-1b (CD5-) [23, 24]. In contrast to B1 cells, mature B2 cells are 
usually derived from the BM. These cells are further subdivided into follicular 
(FOL) B cells, which are localized in the secondary lymphoid tissues, and 
marginal zone (MZ) B cells confined to the MZ of the spleen [25]. 
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1.3 B CELL MALIGNANCIES  
B cell malignancies generally occur at all phases of B cell development. 
Any increase in the growth of lymphoid progenitor cells is known as acute 
lymphoblastic leukemia (ALL). ALL is one of the most common cancers in 
children, with 80-90% survival rate for children and 50% survival rate for adults 
[26]. Expansion of B-lineage cells comprises around 80% of ALL cases. The B-
ALL type is characterized by CD10 expression with no cytoplasmic 
Immunoglobulins (Igs). B-ALL is classified into two types; pre-B-ALL (CD10 
positive with cytoplasmic Igs) and pro-B-ALL (with no CD10 expression and no 
cytoplasmic Igs). Many chromosomal translocations have been found in 
leukemic B cells and are implicated in different malignancies. TEL-AML1 
t(12;21) is a common translocation in children [27]. On the other hand, one of 
the most common translocations in adults is Breakpoint cluster region-Abelson 
murine leukemia viral oncogene homolog, [BCR-ABL t(9;22)] with poor 
treatment outcomes [27, 28]. Gleevec (Imatinib) is used as treatment for ALL 
patients with BCR-ABL translocations, however, there is a high risk of relapse 
due to drug resistance as a result of mutations in the ABL kinase domain. 
Therefore, new lines of tyrosine kinase inhibitors are being developed to treat 
these patients [29]. E2A-PBX1 and FLT3-ITD are other examples of common 
translocation in ALL as well as other malignancies have been shown that 
involve mixed-lineage leukemia gene (MLL) or MYC genes. Patients with these 
translocations are severely affected because of altered cell growth, increased cell 
survival and inhibited lymphocyte differentiation. A large percentage of ALL 
tumors lack translocations and are characterized by hyperdiploidy, with more 
than 50 chromosomes. Loss-of function mutations in genes involved in B cell 
development, such as Pax5, Ikzf1 (Ikaros), and Ebf1 are present in nearly 40% 
of ALL patients [30]. 
Expansion of malignant B cells, by chromosomal translocations, or 
mutations, has been linked to the deregulated activation of many protein tyrosine 
kinases and adaptor molecules [31].  For example, B cell linker protein/SH2 
domain containing leukocyte protein of 65 KDa (BLNK/SLP-65) functions as a 
tumor suppressor in human pre-B cells; therefore, defective expression of 
BLNK/SLP-65 has been documented in nearly 50% of childhood pre-B ALL 
[32, 33]. Furthermore, it has been reported that the tumor frequency of pre-B-
cell lymphomas considerably increases when expression of both BLNK and 
Bruton’s tyrosine kinase (BTK) is compromised, indicating that BTK together 
with BLNK is important for suppressing leukemia [34]. Moreover, 16 pediatric 
patients with BLNK deficiency have been identified in a total of 34 patients with 
pre-B ALL [32]. Thus, the development of ALL seems to frequently occur as a 
result of the defect in some of the genes that play important roles in B cell 
development. Another common B cell malignancy is B cell chronic lymphocytic 
leukemia (B-CLL), which is the most common form of B cell leukemia in the 
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Western world [35]. B-CLL refers to the aberrant expression of CD5 on the 
accumulated monoclonal population of mature B cells [36, 37]. The most 
recurrent chromosomal aberration in CLL is deletion of chromosome 13q14. 
This region includes transcripts encoding miR15 and miR16, which are 
negative regulators of the anti-apoptotic gene B cell lymphoma 2 (BCL2) [38]. 
Another type of B-CLL with poor prognosis is caused by chromosome 17p 
deletion, which harbors the gene encoding for the tumor suppressor p53 protein 
[39, 40]. 
1.4 B CELL RECEPTOR (BCR) SIGNALING 
Depending on the maturation stage of B cells, BCR-mediated intracellular 
signaling is important for B cell development, proliferation and survival. For 
example, BCR signals stimulate the proliferation and survival of mature B cells. 
In contrast, these same signals, enhance apoptosis or inactivation via anergy or 
receptor editing in immature B cells [41]. Functional BCR signaling complex 
comprises of two transmembrane immunoglobulin heavy chains and two light 
chains. BCR is regularly referred to as surface IgM with a very short 
cytoplasmic domain. Therefore, BCR is fixed inside the membrane and 
connected to transmembrane heterodimer components, Igα  (CD79α) and Igβ  
(CD79β), which are necessary for transducing the signals [42, 43]. The 
cytoplasmic terminal portion of Igα and Igβ contain immunoreceptor tyrosine-
based activation motif (ITAM), which is essential for protein binding and 
transduction of downstream signaling [44, 45]. BCR aggregation occurs in lipid 
rafts upon antigen binding, which enables SRC-family kinases, LYN, FYN, 
LCK or BLK to phosphorylate the tyrosines in the ITAM [46, 47]. Moreover, 
phospho-tyrosines in vascular endothelial growth factor receptor 2 (VEGFR2) 
are important for the recruitment of SRC family kinases in vascular endothelial 
cells [48] and BMX/ETK in endothelial cells [49, 50]. Phosphorylated tyrosine 
residues in the ITAM recruit kinases such as spleen tyrosine kinase (SYK) 
leading to their activation and subsequent formation of the signalosome, 
involving SYK, BLNK, BTK, PI3K, PLCγ2, VAV, PKCβ, CARMA1, as well 
as other proteins that propagate activation signals to downstream secondary 
effectors [44, 45, 51-53].  
Several positive and negative co-receptors of the BCR are present on the B 
cell surface and are important for the regulation of BCR signaling. CD19 and 
CD45 enhance BCR signaling [54, 55], whereas CD22, FcγRIIb and PIR-B 
attenuate BCR signaling. LYN can phosphorylate CD19, which creates docking 
site for the SRC homology 2 (SH2) domain of phosphatidylinositol-3-kinase 
(PI3K) leading to generation of phosphatidylinositol 3,4,5-triphosphate (PIP3) 
from phosphatidylinositol 4,5-bisphosphate (PIP2) (Figure 1). The plasma 
membrane-localized phosphatase CD45 can stimulate BCR signaling through 
dephosphorylation of an inhibitory tyrosine in the tail of LYN, which is 
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phosphorylated by the C-terminal SRC kinase, CSK [55]. In contrast to the 
stimulatory effect of LYN on BCR signaling, LYN phosphorylates ITIMs 
(immunoreceptor tyrosine-based inhibition motif) of the CD22 and FcγRIIB 
inhibitory receptors through recruitment of SH2 containing phosphatase (SHP-1) 
and SH2 containing inositol phosphatase (SHIP-1) as well as preventing PI3K 
binding to CD19 [54, 56, 57]. 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1. B cell receptor signaling cascade. BCR transduction is elicited upon antigen 
binding. The balance of the initiation, amplitude and length of BCR stimulation is influenced by 
different molecules, such as kinases (like LYN, SYK, PI3K), adaptors (such as BLNK/SLP65, 
BCAP, CARD11), and the co-regulators (for example CD22, CD19, CD45). Modified from 
[58].  
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homology (PH) domain containing proteins [59]. Several cytoplasmic tyrosine 
kinases and molecules are recruited to the plasma membrane through their PH 
domain, following PIP3 production. After BCR stimulation, activated 
phospholipase-C gamma2 (PLCγ2) generates the secondary messengers; inositol 
triphosphate (IP3) and diacylglycerol (DAG) [60]. Protein kinase C (PKC) and 
calcium mobilization are then activated by DAG and IP3 respectively [61], 
leading to the activation of nuclear factor kappa B (NFκB), nuclear factor of 
activated T cells (NFAT) transcription factor families and JNK [62, 63].  
1.5 PROTEIN TYROSINE KINASES 
Protein tyrosine kinases (PTKs) are important molecules in multicellular 
organisms and are involved in various signal transduction pathways. The PTKs 
are divided into a receptor protein tyrosine kinases (rPTK) group and a 
cytoplasmic, non-receptor protein tyrosine kinase (nPTK) group [64, 65]. The 
nPTK group is also subdivided into several families, including SRC, which is 
the largest family in this group of kinases and TEC family kinases (TFKs), the 
second largest family [66]. 
1.5.1 TEC Family Kinase (TEC) 
The TEC family kinases are cytoplasmic non-receptor tyrosine kinases 
found primarily, but not exclusively, in hematopoietic lineages, where they are 
differentially expressed. Members of this family are: Tyrosine kinase expressed 
in hepatocellular carcinoma (TEC), BTK, IL2-inducible T cell kinase 
(ITK/EMT/TSK), BM tyrosine kinase gene in chromosome X (BMX/ETK) and 
Resting lymphocyte kinase RLK/TXK [67]. These kinases, which have been 
extensively studied, have broadened our understanding regarding lymphocyte 
development and signaling in both cell lines and animal models. They are often 
involved in a variety of cellular processes, including calcium (Ca2+) mobilization 
and activation of PLCγ2, actin reorganization, adhesion, migration (motility) and 
survival/apoptosis [68]. The structures of TEC family members are 50-60% 
conserved and have a similar domain structure. The TEC family members are 
multi-domain proteins consisting of N-terminal pleckstrin homology (PH) 
domain, SRC homology domains 3, and 2 (SH3, SH2), and a C-terminal 
kinase/catalytic domain (SH1/KD). TEC family kinases contain an amino-
terminal PH domain, which is common in several intracellular signaling 
molecules and is able to bind PIP3 for mediating protein-protein interactions 
[69]. 
1.5.2 Bruton’s Tyrosine Kinase (BTK) 
BTK is a cytoplasmic tyrosine kinase belonging to the TEC family of 
kinases. BTK activity is specifically critical for B-lymphocyte development and 
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signal transduction through various receptors, such as FcεRI, interleukin 3 (IL-
3), interleukin 6 (IL-6) and G-protein coupled receptors (GPCR) [66, 70-72].  
Thus, BTK is a central player in pre-B and B-cell signaling initiated by the BCR 
and the pre-BCR, controlling development, proliferation and differentiation of 
B-cell lineages [73]. A point mutation affecting a conserved Arginine (Arg) in 
the PH domain of BTK causes immunodeficiency due to lack of B lymphocytes 
and Abs in humans, a condition called X-linked Agamma-globulinemia (XLA). 
In mice, a similar mutation leads to X-linked immunodeficiency (Xid), a far less 
severe phenotype [74, 75]. 
In 1952, O. C. Bruton discovered a recessive genetic disorder 
characterized by the absence of immunoglobulins, named XLA in patients with 
recurrent bacterial and enteroviral infections [76]. The symptoms appear at a 
very early age with a lack of humoral immunity due to a distinct decline in 
serum Igs of all classes [77, 78]. XLA is initiated after maternal Igs are 
catabolized and absence of L-chain re-arrangements leads to negligible levels of 
new B-lymphocytes and plasma cells being formed. In XLA patients, B-
lymphocyte development is defective with a partial block after pro-B-cell and a 
complete blockage after pre-B-cell phase, leading to absence of B-lymphocytes 
in humans (Figure 2). In contrast, there is only a partial block in Xid mice [79, 
80]. It has been shown in 1993 that the molecular basis of XLA defect is due to 
mutations in a tyrosine kinase, termed BTK [70, 71, 81]. Using different 
approaches, the defective BTK gene in XLA was mapped to the long arm of the 
X chromosome (Xq 21, 3-22 region [82-85]. 
 
 
 
 
 
 
Figure 2.  Early stages of B-cell differentiation can be identified by the genes, the cell surface 
markers CD34, CD19, and surface immunoglobulin (sIg). 
In addition to an N-terminal PH domain, the BTK protein contains SH3, 
SH2 and SH1/KD and an area of 60-80 amino acids among the PH and SH3 
domains named the TEC homology domain (TH). The PH domain of BTK 
associates with numerous proteins, such as PKC, βγ-complexes of heterotrimeric 
G-protein, PIP3, PIN-1, transcription factor (TFII-I), VAV, FAS, F-actin and 
focal adhesion kinases (FAK) [86-90] (Figure 3). TH domains contain proline-
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rich sequences and have been suggested to be involved in the auto-regulation of 
BTK.  
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.  Schematic representation showing the BTK structure. The phospho-tyrosines 
pY223 and pY551 are in red and the regulatory serine/threonine phosphorylation sites are in 
green. Arrows in each domain indicate the interacting partners and/or regulating proteins. The 
R28C mutation found in XID mice causes classical XLA in humans. 
Following BCR stimulation with antigen, tyrosine residues in the 
cytoplasmic tails of Igα/Igβ heterodimers are phosphorylated within the ITAM. 
Members of SRC family kinases carry out the phosphorylation of these residues 
creating docking sites for SYK tyrosine kinases. PI3K is also activated by BCR 
antigen engagement and results in an increase in the PIP3 in the plasma 
membrane, leading to the plasma membrane translocation of many signaling 
proteins including Tec family kinases through their PH domain. BTK signaling 
is believed to predominantly occur in the plasma membrane together with other 
signaling components assembly that leads in the formation of BTK-signalosome 
[72, 91-94]. The membrane-localized BTK is active following transient 
phosphorylation of two of its highly conserved tyrosine residues, tyrosine Y551 
and tyrosine Y223. Tyrosine Y551 in the activation loop of the kinase domain is 
trans-phosphorylated by the SRC family tyrosine kinase LYN. Phosphorylation 
at Y551 induces BTK to undergo a conformational change leading to auto-
phosphorylation at tyrosine residue Y223 within the SH3 domain resulting in 
increased kinase activity [87]. Phosphorylated BTK brings PLCγ2 and BLNK in 
close proximity with SYK, leading to tyrosine phosphorylation of PLCγ2. 
Phosphorylated and activated PLC-γ2 hydrolyzes PIP2 into IP3 and DAG, 
followed by calcium mobilization and PKC activation [46].  
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Since BTK does not have a negative auto-regulatory mechanism to 
modulate its own activity, it seems to entirely depend on the interacting 
signaling partners to regulate kinase activity. Interestingly, a number of well-
known BTK-interacting proteins were shown to function as a negative feedback 
regulator to fine-tune BCR signaling through BTK, such as PKCß, Caveolin-1, 
Peptidylpropyl cis/trans isomerase (PIN-1) and AKT. PKCß was found to down 
regulate BTK activity via direct phosphorylation at Ser-180, which subsequently 
reduces membrane recruitment, trans-phosphorylation and retains BTK in the 
cytoplasm [95]. It has been shown that BTK interaction with caveolin-1 leads to 
down regulation of the BTK kinase activity [96]. The two identified serine 
residues, Ser-21 and Ser-115, of BTK phosphorylated by Pin1, are prerequisites 
for negative regulation of BTK. Phosphorylation of serine 21 leads to Pin1 
binding and guiding BTK during mitosis, whereas serine115 phosphorylation 
leads to Pin1 interaction with BTK in resting cells [86]. Recently, we have 
shown that AKT-induced phosphorylation of BTK at residues Ser-51 and Thr-
495 is required for the 14-3-3ζ interaction and subsequent degradation. In 
contrast, PKCθ activates BTK, whereas BTK down regulation results in the 
induction of the PKCθ activity [97].  
Activation of TEC family kinases is mainly dependent on the synergistic 
action of PI3K and SRC family kinases activity [98], together with JAK/SYK 
family members [99]. The erythropoietin receptor (EPOR) is expressed on B-
lymphocytes and is modulated when treating with recombinant human 
erythropoietin (EPO) [100]. EPO induces downstream signaling by activating 
proteins such as PLCγ and Signal Transducer and Activator of Transcription 5 
(STAT5). On the other hand, BTK is phosphorylated by Janus kinase 2 (JAK2) 
in response to EPO [101].  
1.5.3 Spleen Tyrosine Kinase (SYK) 
SYK is a member of the nPTK family together with zeta-chain associated 
protein kinase 70 (ZAP70) [102]. SYK is an essential player for signal 
transduction initiation in a variety of cell types. The activity of SYK is critical in 
the development of B-cells progenitors and plays a key role in the uncontrolled 
growth of tumor cells, in particular, those of B cell origin [103, 104]. This kinase 
functions downstream of both antigen receptors (BCRs) and Fc receptors (FcRs) 
in various cells and transduce signals leading to calcium mobilization, altered 
gene expression, differentiation, phagocytosis, cell proliferation, survival and 
cytokine production [105, 106]. Moreover, SYK is essential for platelet function, 
particularly in the initiation of some of the integrin, C-type lectin CLEC-2, and 
GPVI receptors [107]. SYK is abundantly expressed in a wide variety of cells 
including all hematopoietic lineage cells as well as non-hematopoietic cells such 
as leukocytes, macrophages, mast cells, platelets, erythrocytes, hepatocytes, 
osteoclasts, fibroblasts, epithelial cells, neuronal and vascular endothelial cells 
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[106, 108, 109]. SYK associates with transmembrane proteins containing ITAM 
upon phosphorylation of the two-tyrosine residues [106]. Recruitment and 
activation of SYK or ZAP70, (the second SYK family protein) in B cell or T 
cells respectively, results in activation of different cellular processes [106]. 
In addition to the above mentioned functions, SYK activation, 
downstream of Dectin-1 in response to microbes to mediate inflammation and 
immunity, results in the production of ROS, activation of MAPK including ERK 
and activation of NFAT by CARD9–BCL-10–MALT-1 and more recently, 
CARD9–H-RAS–RAS-GRF1 signaling complex [110-112]. Moreover, 
activated SYK leads to activation of NFκB via CARD9 as antifungal immunity 
[113]. Therefore, DCs and macrophages with SYK deficiency display impaired 
IL-2, IL-10 and ROS production in response to fungal stimulation [114-116]. 
SYK also has been linked to the regulation of IL-1β production in response to 
fungal infection [114].  
SYK comprises of two-tandem SH2 domains, which are linked by an 
amino acid stretch called interdomain A, and a C-terminal tyrosine kinase 
domain joined with C-terminal of the second SH2 domain via interdomain B 
linker region [117, 118] (Figure 4). Two isoforms of SYK have been described 
as a result of alternative splicing, SYK(L) and SYK(S)/SYKB. SYK(S) has 
identical structure compared to SYK(L), but lacks a 23 amino acid stretch in its 
interdomain B, which has been reported to confer nuclear localization [119, 
120]. SYK(L) is predominantly expressed in the B-cell lineage, whereas the 
shorter isoform SYK(S) is mainly expressed in the BM [121, 122]. The longer 
isoform, SYK(L) is found in both cytoplasm and nucleus, whereas the SYK(S) 
is confined to the cytoplasm [119] . 
Figure 4.  Schematic representation of SYK domain structure showing interacting protein 
partners and regulatory phosphorylation sites. Tyrosines are in red color and serine/threonine in 
green. 
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SYK activation loop tyrosine residues (Tyr525/526) phosphorylation by 
SRC family kinases is required for full activation of the kinase [123]. Moreover, 
autophosphorylation of the linker tyrosine residues of SYK maintains its activity 
in an ITAM independent fashion [124].  Thus, SYK is a proximal signal 
transducer element of the BCR. This, in turn, couples the BCR to the activation 
by recruiting various binding partners, such as, BLNK, PLCγ2/PKC, 
PI3K/AKT, VAV, NFκB and RAS/RAF/ERK [125-133]. In the absence of 
SYK, few if any signals are sent following BCR clustering [134]. SYK stabilizes 
its open conformation (catalytically active form) by employing both a 
phosphorylation and protein-protein interaction approach. Notably, SYK has the 
capability to establish its own positive feedback loop mechanism that can 
convey ITAM tyrosine phosphorylation as wells as its kinase domain 
phosphorylation, independent of SRC family kinases [135]. Moreover, various 
negative regulators of SYK have also been demonstrated. For example, SHP-1 
phosphatase keeps SYK in a dephosphorylated form [136]. Another possible 
mechanism for the negative regulation of SYK is by the E3 ubiquitin ligase, 
Casitas B-lineage lymphoma (CBL) [137]. Once the BCR is stimulated, CBL 
binds the phosphorylated Tyr323 in the interdomain B region of SYK, which 
facilitates ubiquitination as well as proteasomal degradation of SYK [137]. That 
said, it has been shown that Tyr130 phosphorylation in the interdomain A of 
SYK enhances detachment from ITAM, which induces SYK down regulation 
[138, 139]. 
To date, two different chromosomal translocation events involving SYK 
have been identified that give rise to chimeric oncogenes, TEL-SYK and ITK-
SYK [140, 141]. TEL-SYK translocation has been detected in a single patient 
with myelodysplastic syndrome, while ITK-SYK translocation was recurrently 
identified in a subset of peripheral T cell lymphomas. Defects or elevation in the 
expression of SYK has been described in B cell lymphomas because of 
impairments in the differentiation of B-lineage cells [103, 142-145]. Also, SYK 
deficiency has been reported as tumor promoting in breast cancer and melanoma 
[146, 147], whereas, loss of ZAP70 expression results in reduced T lymphocyte 
mediated immunity [148]. Because of the important role of SYK in lymphocyte 
differentiation and proliferation, different hematological malignancies and cell 
transformation have been linked to abnormality of SYK such as pre-B ALL and 
B-CLL [106, 149]. Therefore, developing novel compounds that block SYK 
activity or suppress gene expression of SYK have been examined and used in 
clinical trials for treatment of such disorders [149-152]. 
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1.6 SERINE AND THREONINE KINASE FAMILY 
1.6.1 AKT/PKB structure and signaling 
The protein kinase AKT, also known as protein kinase B (PKB), is a 
serine/threonine kinase that functions downstream of the PI3K signaling 
pathway. AKT signaling plays an important role in the regulation of a plethora 
of cellular signaling events modulating cell growth, proliferation, differentiation, 
survival, glucose uptake, metabolism and angiogenesis [153, 154]. Three 
isoforms of AKT proteins AKT1/PKBα, AKT2/PKBβ and AKT3/PKBγ have 
been identified in humans. The genes encoding these proteins are located on 
separate chromosomes. AKT proteins are members of the AGC kinase family 
with distinct physiological functions, expression and characteristics [155-157] 
(Figure 5). AKT1 is ubiquitously expressed in most tissues and is mainly 
involved in cell growth and survival, while AKT2 expression is limited to 
skeletal muscle, heart, kidney, pancreas and liver and is largely involved in 
insulin signaling and glucose homeostasis. On the other hand, AKT3 expression 
is restricted to the neural tissue and its function is critical for testis- and brain 
development [158-160]. Recently, the involvement of AKT3 in breast cancer 
aggressiveness has also been described [161]. AKT1 knockout (KO) mice show 
dwarfism phenotype in which a reduction in body and cell size occurs [162]. 
Deletion of AKT2 leads to insulin resistance and a diabetes mellitus-like 
syndrome [163]. Deficiency in AKT3 leads to decrease in brain size and 
disorganization of corpus callosum [164]. Importantly, double KO of both 
AKT1 and AKT2 leads to neonatal lethality [165]. The different AKT isoforms 
have a similar structure consisting of PH domain in the N-terminal and α-helical 
linker domain followed by a kinase domain and a hydrophobic regulatory motif 
near the C-terminus [166, 167].  
AKT is recruited and translocated to the membrane via PH domain 
binding to PIP3, where it is activated by PI3K [168, 169]. Following recruitment 
of AKT from the cytosol to the inner leaflet of the plasma membrane and 
binding to PIP3, the AKT conformation is altered, subsequently exposing 
threonine 308 (Thr308) in the activation loop of the kinase domain (residue 
numbers correspond to AKT1) for phosphorylation by the serine/ threonine 
phosphoinositide dependent protein kinase 1 (PDK1), which is also recruited to 
the membrane via its PH domain upon PI3K activation [61, 157, 170, 171]. The 
phosphorylation of AKT at Thr308 in the kinase domain is important for the 
partial AKT activity, which is sufficient to phosphorylate and inactivate proline-
rich AKT substrate of 40 kDa (PRAS40) and tuberous sclerosis protein 2 
(TSC2), which subsequently can directly or indirectly activate mTORC1 [172]. 
Activated mTORC1 further phosphorylates its key substrates, eukaryotic 
translation initiation factor 4E binding protein 1 (4EBP1), and ribosomal protein 
S6 kinase, 70 kDa, polypeptide 1 (S6K-1), which promote protein synthesis and 
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cell proliferation [173]. The mTORC1 structure components are composed of a 
regulatory-associated protein of mTOR (Raptor), PRAS40, mammalian TORC 
subunit LST8 (mLST8)/G-protein β-subunit like protein (GβL), and DEP 
domain containing mTOR-interacting protein (Deptor) [174]. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5.  Domain structure of AKT isoforms showing the phosphorylation sites and regulatory 
partners.  
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RXRXXS/T motif in the target proteins [169, 170, 175-178]. To date, numerous 
AKT interacting proteins are shown to harbor the RXXRXS/T motif. 
Phosphorylation of this motif creates a docking site for 14-3-3 proteins [179, 
180]. At this point, AKT/PKB full activation can mediate various functions 
including angiogenesis, metabolism, growth, proliferation and survival/apoptosis 
[181]. The mTORC2 comprises of several components, involving mTOR, Rictor 
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(Rapamycin insensitive-companion of mTOR), mLST8, Deptor, mSin1 
(mammalian stress-activated protein kinase interacting protein), and Protor 
(protein observed with Rictor-1) [182, 183]. AKT has a transitional role between 
two complexes, mTORC1 and mTORC2. mTORC1 functions downstream of 
AKT, while mTORC2 is known to be an upstream regulator of AKT kinase 
activation [182]. Thus, AKT plays a central role in the cross talk between many 
cellular signaling processes and also acts as a proto-oncogene, which can 
contribute to the development or progression of various human cancer forms 
[184, 185]. Notably, PI3K/AKT pathway is also active downstream of platelet-
derived growth factor receptor B (PDGFRB), fibroblast growth factor receptor 
(FGFR) and VEGFR2 [186, 187]. Tyrosine residues in FGFR create a binding 
site for PI3K/AKT as well as PLC/PKC and RAS/MAPK. Thus, growth 
induction of various tumors have been observed due to increased and 
dysregulated PDGFRB and FGFR levels [186]. Additionally, AKT activity is 
inhibited by mutating domain B of Neuropilins 2 (NRP2), which is a co-receptor 
for VEGF through blocking of VEGF binding to NRP2 [188]. 
Additional proteins are known to be responsible for dephosphorylating 
AKT. Various phosphatases have been shown to dephosphorylate AKT and 
negatively regulate AKT activity. Recently, the PH domain and leucine-rich 
repeat protein phosphatases PHLPP1 and PHLPP2 [189] have been reported to 
dephosphorylate S473 of AKT2 and AKT1, respectively [190]. Phosphatase, 
PP2A inactivates AKT by direct dephosphorylation of the Thr308 residue, and 
Phosphatase and tensin homolog deleted from chromosome 10 (PTEN) converts 
PIP3 to PIP2 by dephosphorylating the 30-position of the inositol ring in PIP3, 
which results in PIP2 production (Figure 6). Thus, PHLPP1/2, PP2A and PTEN 
together participate in the termination of AKT signaling [191-195]. Notably, 
PTEN mutations or loss of its expression constitutively activates AKT signaling, 
subsequently leading to increased growth and prevent apoptosis. Furthermore, 
deficiency of both PHLPP and PTEN is highly correlated with prostate cancer 
[196]. Moreover, mTORC2 activity can be regulated by Sin1 phosphorylation at 
Ser260, which inhibits lysosomal degradation of Sin1 and subsequently 
increases the integrity of mTORC2 [197]. Another way of mTORC2 regulation 
is through Glycogen synthase kinase-3 (GSK-3β) induced Rictor 
phosphorylation at Ser1235 leading to mTORC2 inactivation, which affects the 
capability of substrate binding [198]. Deregulation of the PI3K/AKT pathway 
and increased levels of phosphorylated AKT has been reported in numerous 
cancers, which is concurrent with severe phenotype and poor prognosis. 
Therefore, a balance between the activity of PDK1/AKT/mTORC2 and 
PHLPP/PP2A/PTEN is required for controlling the kinase activity of AKT.  
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Figure 6.  Schematic representation of AKT activation and downstream signaling pathways. 
"Illustration reproduced by courtesy of Cell Signaling Technology, Inc. (www.cellsignal.com) 
with slight modification". 
1.7 ADAPTOR MOLECULES 
1.7.1 14-3-3 family proteins 
The 14-3-3 family proteins are highly acidic proteins expressed in all 
eukaryotic cells [199, 200]. 14-3-3 proteins regulate various cellular processes, 
in particular, apoptosis and cell-cycle checkpoints [201]. In mammals, seven 
isoforms constitute this family denoted as 14-3-3 β, γ, ε, ζ, η, θ and σ [202]. It 
has been reported that the 14-3-3 alpha isoform is the phosphorylated form of 
14-3-3 beta, while 14-3-3 delta isoform is the phosphorylated form of 14-3-3 
zeta [203]. In cells, the overwhelming majority of 14-3-3 proteins exist as both 
homodimers and heterodimers. However, the sigma isoform, which only forms 
homodimers, is the exception [204-206]. 14-3-3 proteins generate dimers that 
creates docking sites for target molecules, functioning as scaffold protein [199]. 
In addition to serine/threonine phosphorylation, association of 14-3-3 also 
requires the full 14-3-3 consensus-motif for complete binding [207]. 14-3-3 
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proteins also act as regulators of many biological as well as cellular functions 
involving cell cycle progression, metabolism, apoptosis, cytoskeleton regulation 
and cytoplasmic sequestration. Cytoplasmic sequestration further facilitates 
targeted protein stimulation/prevention of enzymatic activity, degradation, and 
enabling of protein modification. Therefore, lack of expression and/or function 
of 14-3-3 proteins could contribute to a disarray of cellular activities [208-210]. 
14-3-3 proteins bind to three different consensus-binding motifs; RSXpTXP, 
RXY/FXpTXP and AKT phosphorylation site (RXRXXpS/T), where pT/S 
denotes phospho-serine/threonine [211]. Binding of 14-3-3 to the target protein 
is dependent on the phosphorylation of serine or threonine, which permits the 
conditional interaction of 14-3-3 with protein partners harboring RXRXXpS/T 
motif [211-213]. Moreover, 14-3-3 monomer consists of an amphipathic ligand-
binding groove permitting each 14-3-3 to bind to two different residues of the 
same protein or two different proteins simultaneously. 
The modes of action of 14-3-3 proteins can be generally classified into 
the following categories: (1) direct conformational change of the target protein; 
(2) preventing the target protein from dephosphorylation (3) as adaptors 
(scaffolding molecules), mediate anchoring of proteins in close proximity of one 
another and (4) modulating subcellular localization of target proteins [201, 214, 
215]. Nucleocytoplasmic trafficking of proteins is necessary in the regulation of 
various cellular functions. It has been shown that 14-3-3ζ is present in the 
nucleus and can rapidly shuttle between cytoplasm and the nucleus [216]. 14-3-3 
binding can increase the nuclear export or decrease nuclear import for the target 
protein [217]. 14-3-3 proteins have a nuclear export signal (NES) that can bind 
to the chromosome maintenance region 1 (Crm1), leading to export of 14-3-3 
from the nucleus [218, 219]. The NES sequence in 14-3-3 proteins contains 
amino acids that are also involved in the target binding and thereby compete 
with the Crm1 [220]. The reason that 14-3-3s can be found in the nucleus is 
because the target protein occupies the NES sequence and this indicates that the 
NES signal can be masked for export [221, 222]. However, when the NES signal 
is uncovered, the 14-3-3 can be exported from the nucleus together with its 
target. 
The involvement of 14-3-3 proteins in human cancers is just beginning to 
come to light. Two 14-3-3 family members, 14-3-3ζ and 14-3-3σ have been 
reported to be frequently correlated with tumor initiation and progression. 14-3-
3ζ is implicated in oncogenesis via its association with various cancer initiation 
and progression proteins (BAD, RAF, p85PI3K, FOXO, SNAIL, TGFbetaRI). 
In addition, overexpression of 14-3-3ζ leads to the activation of PI3K-AKT 
signaling pathway thereby down regulating the tumor suppressor p53 [223, 224]. 
Expression of 14-3-3ζ has been reported to be elevated in different human 
cancers, such as stomach cancer, hepatocellular carcinoma and breast cancer 
[225]. As mentioned above, an abnormal increase in the steady-state levels of 
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14-3-3ζ is now considered as a marker for a variety of tumor types [226].  In 
contrast to 14-3-3ζ, 14-3-3σ functions as a tumor suppressor, and reduced 
expression of this protein has been observed in various tumors, such as lung 
carcinomas and breast cancers [227, 228]. The tumor suppressor function of this 
isoform has been attributed to its positive effect in regulating p53 and 
controlling a G2/M checkpoint following DNA damage [229]. In this regard, the 
development of small molecule inhibitors such as BV02, is needed to target 14-
3-3 and exclusively prevent the association of 14-3-3 with partner proteins and is 
promising for anti-cancer therapies [230-232]. 
Notably, 14-3-3 proteins can also be regulated at the level of 
phosphorylation by different kinases. This regulatory mechanism, which is 
currently gaining momentum, suggests that phosphorylation of 14-3-3 at 
different sites (such as Ser58, Ser185 and Thr233) negatively affects association 
with a target proteins and disrupt dimerization of 14-3-3. Various kinases have 
been shown to phosphorylate 14-3-3 at particular sites including certain PKC 
isoforms, PKA, AKT, JNK, CKI and BCR kinases [233-238]. Moreover, K49 
and R56/R60 are key residues in the binding groove of 14-3-3, which mediate 
binding of these proteins to phosphoserine/threonine sites of target proteins. 
Accordingly, mutation of these residues to alanine impairs target-binding ability 
[239, 240].  
1.7.2 ANKRD54 (LIAR) 
Ankyrin repeat domain 54, ANKRD54 (also called Lyn-interacting 
ankyrin repeat, LIAR) is a-300 amino acid scaffold protein corresponding to a-
34 kDa polypeptide. ANKRD54, a cytoplasmic and  - localized protein, is 
important for the assembly of multiple intracellular signaling molecules and 
functions as a scaffold that can regulate signal transduction complexes. The 
nucleo/cytoplasmic shuttling ability of ANKRD54 is due to the presence of a 
functional nuclear localization signal (NLS) and an NES. ANKRD54 (LIAR) is 
widely expressed in various tissues, such as pancreas, prostate, spleen, 
leukocytes, placenta and brain [241]. Furthermore, ANKRD54 has also been 
recognized as a highly expressed protein in ciliated cells [242]. 
ANKRD54 consists of 4 ankyrin repeats in the center of the protein and 
is enclosed by a bipartite NLS motif in the N-terminus and NES motifs in the C-
terminus [241, 243] (Figure 7). The gene encoding human ANKRD54 maps to 
chromosome 22q13.1 and to chromosome 15 E1 in mouse [244]. Notably, 
chromosome 22q13.1 in humans has been linked to leukemia and other cancers. 
The structure of ANKRD54 displays a highly conserved sequence among 
mouse, rat and human [241]. The ankyrin repeats domains have been reported to 
exhibit specificity for protein-protein interaction [106, 245, 246] Ankyrin repeat 
domain sequences occur in approximately 6% of all eukaryotic proteins and 
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typically consist of 33 residues with two antiparallel-helices linked via a loop in 
the core and a pair of β-hairpin at both ends [246]. Moreover, the N-terminal 
region of ANKRD54 contains a potential ATP-binding P-loop (51GLPGRS56) in 
the mouse, but not in the human protein [243]. 
 
 
 
 
Figure 7.  Domain structure of ANKRD54 (LIAR) and interacting protein partners. 
Recently, ANKRD54, with its ankyrin repeats, has been shown to be an 
important partner for various proteins containing SH3 domain, such as ESE2L, 
LASP1, VAV1, Hip55, LYN, HS1 and BTK [241, 243]. Interestingly, the 
interaction of ANKRD54 with the partner proteins seems to be independent of 
the canonical proline-rich consensus binding motif in the SH3 domain [244]. 
Recently, we have demonstrated that ANKRD54 directly interacts with BTK 
and regulates its nucleo/cytoplasmic shuttling in an SH3-dependent manner 
[241]. Similarly, ANKRD54 also associates with Lyn through the SH3-domain 
by forming a multiprotein complex that influences erythropoietin-induced 
differentiation of erythrocytes [243]. Importantly, the association of ANKRD54 
with LYN or BTK is independent of the phosphorylation status and kinase 
activity of these proteins. Moreover, at present, there is no evidence suggesting 
that LYN phosphorylates LIAR [241, 243]. The ankyrin repeats of IκB interact 
with p65 subunit of NFκB, which inhibits p65 translocation to the nucleus and 
thus abolishes the activation of the NFκB signaling cascade [247, 248].  
1.7.3 BLNK (SLP-65) 
BLNK (also called SLP-65 or B cell adaptor containing an SH2 domain, 
BASH) is a cytoplasmic central adaptor protein in B cells without intrinsic 
catalytic function [249, 250]. BLNK, is considered as initial substrates for PTKs 
following BCR-activation [250]. In human B cells, in addition to the full-length 
protein, an alternative splice variant lacking exon 8 (corresponding to amino 
acids 760-828 in the proline-rich domain of BLNK) exists and is referred as 
BLNK-S [251]. Upon BCR engagement and ITAM phosphorylation, BLNK can 
be recruited to the plasma membrane and is phosphorylated by SYK kinase at 
different tyrosine residues that properly connect BTK and SYK with PLCγ2 and 
initiate a cascade of intracellular downstream signaling events [251, 252].  
Moreover, it has been reported that the transcription factor Pax5 is necessary for  
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the regulation of BLNK expression [253]. Furthermore, interaction of BLNK 
with VAV and NCK correlates with cytoskeletal organization in B cells [250, 
251].  
As a result of aberrant signaling in BLNK-deficient mice, both 
physiological as well as pathophysiological role(s) of BLNK have been 
suggested [51]. Lack of BLNK expression in mice results in partial block of pre-
B cell, lack of peripheral B1 B cells, reduced numbers of B2 cells and 
development of pre-B cell lymphoma [33, 34, 51, 254]. It has been shown that 
malfunction of BLNK leads to immunodeficiency as well as a reduction in the 
activation of PLCγ2 [51, 255]. Moreover, 50% of pre-B ALL in childhood is 
caused by defective BLNK expression, suggesting that BLNK plays a key role 
in pre- B cell differentiation and tumor suppression [32].  
Structurally, BLNK consists of highly conserved N-terminal leucine-
zipper motif important for its membrane tethering, followed by an N-terminal 
region containing tyrosines in YxxP formula, a proline-rich domain and a C-
terminal SH2 domain [51, 256, 257]. BLNK serves as an adaptor molecule to 
assemble various components in the form of signalosome complex to regulate 
signal transduction via inducible docking sites of the phosphotyrosine N-
terminus domain, proline rich domain and SH2 domain, such as HPK1, SYK, 
BNAS2, Growth factor receptor-bound protein 2 (Grb2), VAV and NCK (Y72) 
PLCγ2 (Y84, Y178, Y189), BTK  (Y96) [255, 258-261] (Figure 8). This, in 
turn, couples the BCR to the activation of, among others, the PLCγ/PKC, 
PI3K/AKT, NFκB and RAS/RAF/ERK signaling pathways [125-129]. 
Moreover, BLNK can bind to phospho-tyrosine 204 (pY204) in the ITAM 
region of Igα for its activation [262]. 
 
 
 
 
 
 
 
 
Figure 8. Schematic representation of BLNK domain structure showing regulatory 
phosphorylation/degradation residues as well as interacting protein partners. 
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According to a recent study, HPK1 phosphorylates BLNK at threonine 
152 (T152) thereby creating a binding site for 14-3-3 proteins [263] that 
facilitates ubiquitination, and proteasomal degradation of BLNK [263] (Figure 
8). Different modes of interactions have been suggested with respect to the 
translocation of BLNK to the plasma membrane and the triggering of B cell 
activation. It has been reported that BLNK requires a constitutive association 
with the CBL-interacting protein of 85 kD (CIN85) to control their subcellular 
location [264]. Also a putative leucine zipper motif in the N-terminal basic 
domain of BLNK could be important for membrane binding [257]. Furthermore, 
it has been proposed that CMTM7 acts as a transmembrane linker of BLNK and 
BCR [265]. In the current study (Paper IV), we have identified that 14-3-3 is an 
important regulator for binding of BLNK with SYK and controlling BCR 
downstream signalosome (Mohammad, et al., 2015).  
1.7.4 Karyopherins (Importins) 
Karyopherins are a group of adaptor molecules responsible for 
transporting target proteins. Karyopherins comprise of Importins [266] and 
Exportins [267, 268], which mediate nuclear import and export, respectively. 
The most classical nuclear protein import pathways are mediated by Importin β 
and Importin α, which are also known as Karyopherin β1 (KPNB1) and 
Karyopherin α (KPNA) respectively. In this classical pathway many cargoes 
bind directly to Importin α, which serves as an adaptor protein to tether the cargo 
to Importin β forming a trimeric transport complex that moves through the 
nuclear pore into the nucleus. Importin β is composed of 19 HEAT repeats, 
structural motifs consisting of two antiparallel helices connected by a short loop 
[269]. These HEAT repeats are stacked to form superhelical structures [270]. 
The HEAT repeats (1-8), (3-8) and (7-19) in Importin β are important for 
RanGTP, nuclear pore complex (NPC) and Cargo/Importin α binding (Figure 
9A). The number of Importin β subunits differs between organisms. The genome 
of Saccharomyces cerevisiae encodes for 14 Importin β subunits, whereas the 
genome of human encodes for 20 Importin β subunits, of which 10 are Importins 
and 7 are exportins [271]. Importin α subunits are composed of a flexible N-
terminal Importin β binding (IBB) domain, ten armadillo (ARM) motifs, and an 
acidic C-terminal domain (Figure 9B). The IBB domain of Importin α serves as 
the binding site for Importin β.  
The classical nuclear import cycle is the most used pathway for 
nucleocytoplasmic transport inside cells. In this cycling, cargo proteins are 
recognized by Importin α, which links the target proteins to Importin β [272].  A 
trimeric complex is formed and translocation into the nucleus occurs via 
Importin β-mediated association with the nuclear pore. In the nucleus, the 
trimeric complex dissociates as a result of a conformational change of Importin 
β after binding of RanGTP, which results in the release of the cargo-Importin α 
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complex [273]. Next, the auto-inhibitory region on the IBB of Importin α, the 
Cse1 and Nup2 facilitate delivery of the target protein into the nucleus [274-
279]. To fulfill another round of cargo import, Importin α is recycled back to the 
cytoplasm with help of the export receptor in complex with Ran/GTP, 
Cse1/RanGTP (Figure 10) [280, 281]. Thus, Importin β-like proteins are able to 
translocate target proteins, using different modes, such as direct canonical and 
NLS-dependent or direct non-canonical NLS-independent cargo binding and 
form a complex with Importin α or with other β-like Importins. 
 
 
 
 
 
 
 
 
Figure 9.  Domain structure of Importin β (A) and Importin α (B). 
Importin-7, also called (Ran-binding protein 7), a 120 KDa protein of 
1036 amino acids is a cytoplasmic and nuclear protein that is ubiquitously 
expressed in most tissues [282]. Importin-7 functions in the nuclear transport of 
target proteins as a nuclear transport receptor or a scaffold protein in association 
with other Importins, such as Importin 3 [283, 284]. Importantly, increase in the 
steady state of Importin 7 has been detected in different cancer cells, such as 
colorectal carcinoma, breast and ovarian tumors [285, 286], which might be a 
good candidate for drug improvement. Importin-7 is considered to act as 
receptor for proteins harboring NLS to facilitate their translocation via the NPC 
by Ran-dependent mechanism [287].  
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Figure 10.  A schematic overview of the Importin β and Importin α nuclear import and export 
cycles. 
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2 AIMS 
2.1 GENERAL AIMS 
The overall aim of this thesis was to investigate alterations in the signalosome 
assembly downstream of the BCR signaling following stimulation of this 
receptor. In particular, the role of AKT and 14-3-3 in the regulation of this 
signalosome complex down stream of BCR signaling in B cells was 
investigated. Our aim was to get insight into the molecular mechanisms 
responsible for these regulations and explore new pathways that could enable us 
understand the consequences of the B cell malignancies that may contribute to 
the development of new treatment strategies. 
2.2 SPECIFIC AIMS 
• To study the role of AKT and 14-3-3 in the regulation of intracellular 
signaling of BTK in B cells. 
• To investigate the role of ANKRD54 (LIAR) in the nucleo/cytoplasmic 
shuttling of BTK. 
• To characterize newly identified protein-binding partners downstream 
of AKT-mTORC1/2 signaling. 
• To explore the potential role of AKT, 14-3-3 and Importin 7 in the 
regulation and subcellular localization of BLNK and SYK.  
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3 MATERIALS AND METHODS 
3.1 CELL LINES  
Namalwa (human Burkitt lymphoma B-cells), K562 (human chronic 
myelogenous leukemia cells), A20 (mouse B-lymphoma), Nalm-6 (pre-B-cell 
leukemia), RBL- 2H3 (rat basophil leukemia cells with mast cell characteristics), 
Jurkat (human T-lymphocyte), Phoenix GP and PG13 (retrovirus producer lines 
based on human embryonic kidney HEK293T cells), and NIH 3T3 (mouse 
embryonic fibroblast) and Cos-7 (African green monkey fibroblast-like kidney) 
cell lines were obtained from the American Type Culture Collection (ATCC). 
All hematopoietic cell lines were cultured in RPMI1640 medium supplemented 
with 10% heat inactivated Fetal Bovine Serum (FBS) (Life technologies). The 
adherent cell lines were cultivated in Dulbecco´s Modified Eagle’s Medium 
(DMEM) supplemented with 10% heat inactivated FBS. All cell lines were 
cultured at 37 oC in a humidified 5% CO2 incubator.  
3.2 MASS SPECTROMETRIC ANALYSIS 
Mass spectrometry (MS) is a powerful chemical analytical technique that 
requires high-energy electrons for breaking a protein into small peptides.  The 
peptides are further breaking down into ions, which basis on the measurement of 
the atomic mass of each molecule [288]. MS is used to identify the chemical 
structures of the unknown proteins isolated from natural sources. MS is also 
combined with chromatographic separation methods for detection of proteins in 
a mixture [289]. Here, in this study, Namalwa cells were used for MS analysis 
after specific treatment according to the purpose of the project. Namalwa cells 
were lysed with lysis buffer and incubated on ice for 20 min, with intermittent 
mixing. For pre-clearing, protein A and G sepharose beads and agarose anti-IgG 
were added to each tube. We incubated the samples by rotating for 60 min at 
4°C, followed by centrifugation (3000 rpm) at 4°C for 10 min. The supernatants 
were filtered to new tubes containing 50 µl of Flag M2 agarose beads or 
Dynabeads (Life Technologies). The samples were incubated under rotating 
conditions at 4°C. The beads/Dynabeads were washed several times with PBS, 
using centrifugation or magnetic beads, when using Dynabeads. The 
beads/Dynabeads were subsequently washed three times with cold Flag-rinsing 
buffer. The purified protein complexes on the anti-Flag M2 agarose beads or 
Dynabeads were gently eluted with 2% NH4OH and lyophilized, and prepared 
for gel-free mass spectrometry analysis. Samples were digested in solution and 
analyzed by liquid chromatography-MS using high performance liquid 
chromatography (HPLC) system coupled to an LTQ-MS or a capillary HPLC 
system combined to an LTQ-Orbitrap-MS. The resulting MS/MS spectra were 
analyzed using the MASCOT program against the human Ensembl Database 
release. To biochemically validate the proteins identified by MS/MS data, co-
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immunoprecipitation experiments, western blot analysis and Immuno-
fluorescence assays were performed. 
3.3 TRANSFECTION METHODS 
3.3.1 RNA interference 
Small interfering RNAs (siRNAs) are major effectors in the RNA 
interference (RNAi) pathway, comprising double-stranded RNA molecules (20-
25 base pairs in length) that prevent gene expression, primarily by inducing 
degradation of specific messenger RNA (mRNA). For transfection of siRNA, 
100 nM of 14-3-3 siRNA (Santa Cruz) or a “scrambled” sequence with no 
significant homology to any known gene sequences was used. The siRNA was 
diluted in a Buffer R (Neon electroporation Kit; Invitrogen, Carlsbad, CA) and 
added to 1.5 million Namalwa cells in a final volume of 10 µl per reaction. The 
transfection was carried out using the Neon electroporation system according to 
the manufacturer’s instruction. Cos-7 cells were also used for knockdown assay, 
using Lipofectamine 2000, (Life technologies), the procedure of 14-3-3 siRNA 
was performed according the manufacturers protocol. 48 h post transfection, the 
cells were harvested and following lysis processed for western blotting analysis. 
3.3.2 Plasmid transfection 
For adherent cells, transient transfections of the plasmids encoding specific 
proteins were performed in 6-well plates using the cationic polymer 
polyethyleneimine (PEI) (Polysciences Inc. USA), according to the 
manufacturer’s protocol.   
3.4 PROTEIN ANALYSIS 
3.4.1 Immunoprecipitation (IP) 
Immunoprecipitation is one of the methods used for protein precipitation 
and purification. The principle of an IP is based on using a specific antibody 
against a target protein forming an immune complex. This complex can then be 
captured on beads onto Protein A or G. Following IP, the protein partners are 
analyzed using Western blotting. IP analysis was performed using Dynabeads 
protein G (Life Technologies) according to the manufacturer’s protocol. Whole 
cell lysates were incubated with the indicated antibodies and rotated at 4 °C for 2 
h. To co-IP the antibody-antigen complex, 50 µl of protein G Dynabeads were 
added and the mixture was incubated by continuously rotating at 4 °C for 1 h. 
The Dynabeads were washed three times with PBS buffer, suspended in sample 
buffer, boiled at 65 °C for 4 minutes and the resultant analyzed by sodium 
dodecyle sulphate, SDS-PAGE. Negative controls for co-IPs were lysates 
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prepared under the same conditions with the addition of a control antibody (anti-
HA). 
3.4.2 Western blotting  
Western blot (WB) or immunoblot is an important analytical technique 
used in cell and molecular biology research for detecting proteins in 
phosphorylated or native states. By using a WB, investigators are capable of 
distinguishing specific proteins from a complex mixture of proteins isolated 
from cells. The Western blot method was developed in the laboratory of Harry 
Towbin [290]. To facilitate lysis of cells, various detergents, buffers and salts 
can be added. Using a cocktail of phosphatase and protease inhibitors can inhibit 
degradation and dephosphorylation of sample proteins. Gel electrophoresis is 
usually used in order to separate the macromolecules. To facilitate antibody 
detection of the specific protein, the proteins are transferred from the gel and 
blotted onto a nitrocellulose membrane. To reduce non-specific binding, the 
membrane is blocking with a 5% bovine serum albumin (BSA) or LICOR-
Blocking buffer depending on the specificity of the primary antibody. After 
blocking, a dilute solution of primary antibody is incubated with the membrane 
under gentle agitation. Following incubation of the primary antibody, the 
membrane is extensively washed (to remove unbound primary antibody), and 
further incubated with a LICOR secondary antibody (mentioned before). Finally, 
the membrane is again washed to remove unbound antibody and the protein of 
interest is detected using Odyssey infrared imaging system (Li-COR Biosciences 
GmbH, USA). 
3.5 MICROSCOPY  
3.5.1 Immunocytochemistry  
Immunocytochemistry is a frequently used laboratory technique that is 
used to anatomically identify expression and localization of a specific protein in 
cellular compartments with the help of a specific antibody recognizing the 
protein of interest. 16 h after seeding, cells were transfected with plasmids or 
siRNA and left to grow for an additional 48 h. For immunostaining, cells were 
washed several times with PBS and fixed with 2.5% formaldehyde for 15 min at 
room temperature. The fixed cells were subsequently permeabilized using 0.1% 
Triton X-100 in PBS for 15 min, blocked in 0.1% c-BSA for 1 h at room 
temperature and following addition of primary antibodies, incubated overnight at 
4°C. The cells were washed and further stained with a Cy3-conjugated goat anti-
mouse IgG (1:500) or with a fluorescein isothiocyanate (FITC)-conjugated anti-
mouse IgG (1:500). Finally, the cells were incubated with DAPI 5µg/ml DAPI 
diluted in PBS (4=6-diamidino-2-phenylindole, dihydrochloride) (Molecular 
Probes) to stain cell nucleus and then intensively washed prior to imaging. 
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3.5.2 Confocal microscopy 
To obtain high-resolution optical images of the cells, images were 
captured on a Leica DMRXA confocal microscope equipped with a 3D digital 
microscopy workstation (©Leica Microsystems, Wetzlar, Germany). Captured 
images were processed and analyzed using slide book (Intelligent imaging 
Innovations, Inc. Denver, Colorado, USA). 
3.5.3 Fluorescence microscopy 
Following the immunocytochemistry technique, co-localization of the 
indicated proteins was monitored using fluorescence microscopy. Images were 
captured using Olympus microscope (Olympus-IX81). For image processing, 
the cellSense Dimension software (Olympus, Tokyo, Japan) was used. 
3.6 CELL PROLIFERATION AND VIABILITY ASSAY 
Assays to measure cell proliferation, viability, and cytotoxicity are 
normally used to monitor the response of cells in culture following treatment 
with various drugs. Various assays are currently available for determining cell 
proliferation. These assays, which can only estimate cell number, are based on 
measurements related to metabolic activity (MTT or Alamar blue).  In our study, 
we used a cell proliferation assay, which is capable of monitoring the number of 
cells over time as well as the number of cellular divisions. The Countess™ 
automated cell counter from Life Technologies using the viability trypan blue 
dye can provide both the rate of proliferation as well as the percentage of viable 
cells. 
3.7 NUCLEAR AND CYTOPLASMIC FRACTIONATION 
To determine the subcellular localization of different proteins inside the 
cellular compartments, cytoplasmic and nuclear extracts are used instead of 
whole cell lysates. In our studies, we used NE-PER Nuclear and Cytoplasmic 
Extraction Reagents Kit (Pierce), which allows a stepwise lysis of cells that 
generates both functional cytoplasmic and nuclear protein fractions. Namalwa 
nuclear and cytoplasmic extracts were prepared according to the manufacturer’s 
protocol. 
 
3.8 IN VITRO KINASE ASSAY 
In vitro kinase assay is a specific method used to measure the enzymatic 
activity of protein kinases. To achieve this, an antibody specific to the kinase is 
added to the cell lysate in one side and the specific antibody targeting the 
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expecting substrate to another cell lysate will be added. The antibody will bind 
to the desired target kinase and the target protein. The mixture is incubated with 
the protein G Dynabeads separately. Then the Dynabeads from both mixtures 
are incubated in the presence or absence of ATP (200 µM) in a kinase reaction 
buffer for 30 min at 30 °C. After the incubation, the reactions were stopped by 
addition of sample buffer and the proteins were run on 4-12% Bis-Tris SDS-
PAGE gel and phosphorylation visualized by Western blot analysis. If the 
substrate was phosphorylated by the kinase, it appears on the membrane. If the 
kinase was inactive or was unable to phosphorylate the chosen substrate, the gel 
remains blank. The kinase assays can be run on recombinant kinases, or cloned 
and purified from a protein expression system. They don’t necessarily need to be 
isolated from the host cells. In our study immunoprecipitated AKT from 
Namalwa cells was incubated with immunoprecipitated BLNK or SYK and in 
vitro kinase assay was performed. 
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4 RESULTS AND DISCUSSIONS  
4.1 PAPER I 
Dual Phosphorylation of BTK By AKT/Protein Kinase B Provides Docking 
for 14-3-3ζ, Regulates Shuttling, and Attenuates both Tonic and Induced 
Signaling in B Cells 
In this work, we studied the role of 14-3-3 protein, as a novel BTK-
interacting partner. We undertook a mass spectrometry approach and proteomics 
analysis to dissect the BTK signalosome complex and identify novel BTK-
interacting proteins. We performed the proteomic analysis using the 
hematopoietic cell line, Namalwa, as described in our recent papers [231, 241]. 
After analyzing the MS/MS data of the highest peptide coverage, we detected 
the presence of 14-3-3 isoforms (zeta 37.5% and gamma 28.3%) as BTK 
binding partner proteins. To biochemically confirm this finding, we carried out 
western blotting analysis of the BTK signalosome complex and identified 14-3-
3ζ protein, as one of the novel interacting partners for BTK in vivo (of B-cell 
lines and of primary B-lymphocytes). The 14-3-3ζ-protein family is known to 
bind serine/threonine-phosphorylated proteins [212, 291]. Affinity purifications 
have revealed hundreds of interacting partners for the 14-3-3 in humans [292].  
Notably, a novel consensus motif (RXRXXpT/S) known as a target site for 
AKT/PKB phosphorylation was important for the analysis, since this motif also 
functioned as a binding site for 14-3-3ζ [293]. By careful inspection of the BTK 
sequence, we found two AKT/PKB consensus sites, one located in the PH 
domain and the other in the kinase domain. Indeed, the motifs (numbered after 
the BTK sequence) 46-RGRRGpS-51 and 490-RHRFQpT-495 are the perfect 
matches of the AKT target sites; therefore we focused on these two motifs, 
which we considered potentially important as 14-3-3ζ binding-sites. Here, we 
identified that the corresponding sites in BTK were phosphorylated by the 
AKT/PKB that facilitates interaction with 14-3-3ζ through a phosphorylation 
dependent mechanism. Furthermore, we identified from the sequence alignment 
that the 14-3-3 binding region in BTK is highly conserved across species. 
 Our previous studies have shown that BTK is mainly cytoplasmic and 
redistributes to the inner cytoplasmic membrane upon PI3K activation [294]. On 
the other hand, the nucleocytoplasmic shuttling of 14-3-3 and BTK has been 
shown in separate studies, but the shuttling mechanism and the functional 
consequences remain elusive for both proteins [216, 295]. Therefore, it was 
tempting to see if 14-3-3 can regulate the subcellular localization of BTK. 
Interestingly, siRNA knockdown of 14-3-3ζ increased the nuclear translocation 
of BTK, while overexpression of 14-3-3ζ resulted in accumulation of BTK in 
the perinuclear region. 
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In addition, whereas the S51A/T495A-BTK mutant failed to bind 14-3-
3ζ, the phosphomimetic mutant S51D/T495D-BTK enhanced the interaction 
capacity with 14-3-3ζ upon treatment with the proteasome inhibitor (MG132). 
The PI3K inhibitor (LY294002) and/or dominant negative AKT (AKT-DN) 
blocked BTK-serine/threonine phosphorylation and abolished BTK interaction 
with 14-3-3ζ. Moreover, two newly characterized inhibitors 14-3-3 inhibitor 
(BV02) [296] and Ibrutinib (PCI-32765) inhibitor [297] interrupted binding of 
14-3-3 to BTK. Remarkably, S51D/T495D-BTK mutant displayed enhanced 
tyrosine phosphorylation and strong binding to 14-3-3ζ, which subsequently 
induces BTK ubiquitination and degradation thereby attenuating the BCR-
signaling pathway. In stark contrast, the S51A/T495A mutant completely failed 
to become phosphorylated and was not at all ubiquitinated (Figure 11). Although 
cell membrane tethering of the PH domain is key for the activation of BTK, 
nuclear-localized BTK has been reported [298]. In previous studies, we and 
other groups have shown several proteins that negatively regulate BTK, 
including peptidylprolyl cis/trans isomerase Pin1, Caveolin-1 and PKCβ [86, 95, 
96]. Through my work, we now also identify another kinase AKT as a novel 
negative regulator of BTK, through phosphorylation on two sites that facilitates 
its interaction with 14-3-3ζ, which contributes to the termination of B-cell 
receptor signaling.  
 
 
 
 
 
 
 
 
 
 
Figure 11.  Schematic view of the BTK signalosome complex regulation by 14-3-3 protein. 
PI3K-mediated activation of AKT/PKB leads to phosphorylation of BTK at S51 and T495. 
Subsequently, 14-3-3z interacts with phospho-BTK-S51/T495 and prevents translocation of 
BTK to the nucleus.  Moreover, binding of 14-3-3z to activated BTK stimulates ubiquitination 
and degradation of active BTK, leading to the termination of BCR signaling.  
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4.2 PAPER II 
Regulation of Nucleocytoplasmic Shuttling of Bruton's Tyrosine Kinase (BTK) 
through a Novel SH3-Dependent Interaction with Ankyrin Repeat Domain 54 
(ANKRD54) 
In this study, the BTK signalosome assembly was the main focus to study 
interactome of BCR under starved, activated and Btk-inhibited conditions. In 
this work, we generated a stably Flag-tagged BTK expressing Namalwa B-cell 
line and Flag-affinity purification was used to capture signalosome complexes, 
followed by top-down mass spectrometry approach is applied on gel-free 
samples in order to identify novel BTK-interacting proteins. After proteomics 
analysis of the MS-MS data, we selected a novel interactor with BTK, an 
ANKRD54, which we found specifically influences nuclear shuttling of BTK 
[241]. Moreover, we further characterized the interaction between BTK and 
ANKRD54 using biochemical analysis and also by subcellular localization using 
confocal microscopy. Interestingly, we found that ANKRD54 potently 
sequesters BTK in the cytoplasm. In a similar fashion, TXK (RLK), another 
TFK, was also excluded from the nucleus in the presence of ANKRD54. During 
our analysis of ANKRD54, murine LIAR (LYN-interacting ankyrin repeat 
protein- ANKRD54) was published as a novel Lyn-binding protein through the 
SH3-domain and forming a multiprotein complex and influencing 
erythropoietin-induced differentiation of erythrocytes [243]. We also found that 
ANKRD54 modulates nuclear localization of BTK in an SH3-dependent 
manner, while two other nuclear-resident proteins, estrogen receptor beta (ERβ) 
and transcription factor T-bet (T-Box expressed in T cells) were unaffected. A 
peptide consisting of 22 amino acids from the C-terminus of the BTK SH3 
domain (ARDKNGQEGYIPSNYVTE-AEDS) was sufficient for the pull-down 
of endogenous ANKRD54. 
In a previous study, we also observed that the SH3-domain is a negative 
regulator of the nuclear shuttling of BTK, since a BTK-∆SH3 mutant 
predominantly localized to the nucleus at steady-state conditions [298]. In this 
work, we observed that green fluorescent protein-tagged (GFP)-BTK-∆SH3-
NLS, behaved similarly to the GFP-BTK-NLS fusion in being exclusively 
nuclear. Importantly, ANKRD54 failed to interact with GFP-BTK-∆SH3-NLS 
protein and prevent it from entering the nucleus. In contrast, in the presence of 
ANKRD54, the GFP-BTK-NLS protein became completely excluded from the 
nucleus. Also, we showed that the efficacy of cytoplasmic retention of GFP-
BTK-NLS, but not that of the GFP-BTK-∆SH3-NLS fusion, by ANKRD54 is 
compromised in the presence of overexpressed BTK-SH3 domain. In addition, 
active BTK is required for the in vivo tyrosine phosphorylation of ANKRD54, 
suggesting that ANKRD54 may be a direct substrate of BTK. Collectively, 
these data suggest that the SH3 domain of BTK is crucial for ANKRD54 
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interaction, resulting in BTK retention in the cytoplasm. Our results show a 
novel and potentially important partner for BTK in B-lymphocytes, and that 
ANKRD54 controls BTK shuttling into the nucleus in an SH3-dependent 
manner (Figure 12). 
Figure 12. Graphic model of the BTK nucleocytoplasmic shuttling mediated by the SH3-
domain dependent interaction with LIAR (ANKRD54) [241]. 
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4.3 PAPER III 
B Cell Receptor (BCR) Activation Predominantly Regulates AKT Associates 
Motifs Phosphorylation in Proteins Related to RNA Processing 
In the present study, we employed affinity purification of endogenous 
proteins harboring RXRXXpS/T motif, as an mTORC2/AKT consensus 
substrates, towards pull down of complex proteins in Namalwa B cells. To 
identify novel phosphorylated proteins containing the AKT consensus motif, we 
performed proteomic analysis on Namalwa cells using mass spectrometry 
(MS/MS) technique. The peptide coverage for the 446 novel proteins found in 
the proteomic data was obtained following Mascot prediction scoring. To 
biochemically confirm the data of the MS/MS analysis, immunoprecipitated 
enrichment of endogenous proteins containing AKT consensus motif were 
resolved on SDS-PAGE and immunoblotted with phospho-specific 
(RXRXXpS/T) motif antibody, as an AKT consensus substrate. To further 
verify the proteomics data, we investigated the phosphorylation of two of the 
identified proteins Myocyte-specific enhancer factor 2D (MEF2D) and RNA-
binding motif 25 (RBM25) in Namalwa cells. Immunoprecipitation with anti-
MEF-2D and RBM25 antibody resulted in the pull-down of endogenous MEF-
2D and RBM25 followed by immunoblotting with anti-RXRXXpS/T 
demonstrated positively the phosphorylation of both proteins on the AKT-
consensus motif, suggesting that these proteins are downstream substrates of the 
mTORC2/AKT pathway. 
Using MS/MS raw-data, we performed a detailed bioinformatics analysis 
and identified at least 186 proteins containing the RXRXXS/T consensus motif. 
In addition, we also found the 260 proteins, which lack a canonical AKT motif, 
but were present in the complex. Moreover, we detected only 85 proteins that 
were up regulated, while 277 proteins were down regulated following anti-IgM 
stimulation. With respect to the up regulated proteins, a group of ribosomal 
proteins were overrepresented. Another group that seems to be affected are 
proteins, which regulate the cell cycle through various mechanisms, including 
DNA binding and transcriptional regulation factor proteins. Other ribosomal 
proteins were enriched among the down regulated proteins, as were proteins 
involved in ribosome biogenesis. The largest group found to be down regulated 
in the phosphoproteome, consisting of proteins related to RNA binding and 
splicing and mRNP export. These proteins are most likely components of the 
late spliceosomal complexes linked with mRNP export, as described in a 
previous study [299]. 
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4.4 PAPER IV 
AKT/PKB Attenuates SYK and BLNK through 14-3-3 Impairing Nuclear 
Translocation of SYK via Importin 7 in B Cells 
In our recent study, we have characterized the role of AKT/PKB on the 
phosphorylation status of BTK that facilitates the docking of 14-3-3ζ [231]. 14-
3-3 proteins interact with a plethora of signaling proteins to fine-tune the BCR 
activation, thereby controlling cell proliferation, differentiation and/or apoptosis. 
Therefore, we sought to study the proteomics of AKT consensus motif 
RXRXXS/T following BCR engagement. The mass spectrometry (MS/MS) data 
and analysis of protein sequence using Scansite 3 program 
(http://scansite3.mit.edu/) identified BLNK and SYK as target candidate 
sensitive for AKT activity. Although SYK and BLNK are known as proximal 
signal transducer elements of the BCR, little is known about the molecular 
mechanisms underlying 14-3-3 interactions with BCR downstream signalosome.  
Here, we describe that the adaptor protein14-3-3 interacts with SYK and 
BLNK in a Ser/Thr phosphorylation-dependent manner. We found that 
AKT/PKB induces BLNK and SYK Ser/Thr phosphorylation, promoting their 
association with 14-3-3. Moreover, the AKT/PKB inhibitor MK-2206 reduces 
the phosphorylation of BLNK and SYK. In addition, 14-3-3 is required for the 
stable interaction between SYK and BLNK. Furthermore, 14-3-3 attenuates 
SYK binding to Importin 7 and thereby abrogates shuttling to the nucleus. The 
mechanism of nuclear translocation of SYK is not known. In a previous study, it 
was suggested that the unconventional shuttling sequence present in SYK is 
critical for subcellular localization of SYK [300]. To understand the biological 
role of 14-3-3 on SYK translocation to the nucleus, we treated Namalwa cells 
with BV02, a novel 14-3-3 inhibitor and show that 14-3-3 altered the subcellular 
localization of SYK. To further explore the consequences of the 14-3-3 and 
SYK interaction on the translocation of SYK to the nucleus, we pre-treated 
Namalwa cells with BV02 and subsequent co-immunoprecipitation analysis 
revealed that inhibition of 14-3-3 activity using BV02, resulted in the increased 
interaction of SYK with Importin 7. Here, for the first time we report a novel 
association of Importin 7 with SYK that modulates the nuclear shuttling of SYK. 
Collectively, these results suggest that 14-3-3 plays an important role in the 
nucleocytoplasmic shuttling of SYK by controlling the stable interaction 
between BLNK and Importin 7 (Figure 13). 
 
 
 
 
 
 
 DARA MOHAMMAD                                                                                              35 
Chapter 4: Results & Discussions 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 13.   A model illustrating the regulation of BLNK and SYK function by AKT and 
14-3-3. (A). AKT phosphorylates BLNK and SYK in the cytoplasm leading to the 
recruitment of 14-3-3. Furthermore, 14-3-3 binding to SYK interferes with its interaction 
with Importin 7 impeding translocation of SYK to the nucleus. Therefore, for the nuclear 
translocation of SYK, de-assembly of the SYK/BLNK/14-3-3 complex is required. (B). AKT 
phosphorylation sites in SYK are crucial for the modulation of SYK phosphorylation at 
Y525/526, as well as phosphorylation of BLNK at residue Y84. Notably, AKT and HPK1 
phosphorylate BLNK at S285 and T152, respectively, thereby attenuating the activity and 
signaling of BLNK. 
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5 CONCLUSIONS  
The studies in this thesis have shown that: 
Paper I: 
• AKT/PKB is the serine/threonine kinase responsible for the 
phosphorylation of BTK on two sites (Ser51 and Thr495). 
• 14-3-3 is a novel interacting protein partner for BTK. 
Paper II: 
• ANKRD54 (LIAR) specifically influences nucleocytoplasmic shuttling 
of BTK and the association is mediated through the SH3 domain. 
• The interaction between BTK and ANKRD54 (LIAR) is independent of 
the BTK kinase activity. 
Paper III: 
• MEF2D and RBM25 were identified as novel AKT-mTORC1/2-induced 
phosphorylation substrates following B cell receptor activation. 
• BCR activation causes selective up- and down regulation of 
mTORC2/AKT target sites related to ribosome biogenesis and RNA-
processing. 
Paper IV: 
• AKT/PKB induces BLNK and SYK Ser/Thr phosphorylation and 
facilitates docking sites for 14-3-3 and Importin 7 interaction, thereby 
regulating translocation of SYK to the nucleus. 
• AKT phosphorylation sites (Ser295/Ser297) in SYK are important for 
controlling SYK Y525/526 phosphorylation. 
• BLNK phospho-tyrosine 84 (pY84) correlates with the SYK phospho-tyrosine 
525/526 level. 
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